✦ LIBER ✦

Pituitary adenoma: The efficacy of radiotherapy as the sole treatment

✍ Scribed by Stephen C. Rush; Joseph Newall

Publisher: Elsevier Science
Year: 1989
Tongue: English
Weight: 612 KB
Volume: 17
Category: Article
ISSN: 0360-3016
DOI: 10.1016/0360-3016(89)90384-2

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Sarcoma of the sella after radiotherapy

Sarcoma of the sella after radiotherapy for pituitary adenoma

✍ Sven Berkmann; Markus Tolnay; Daniel Hänggi; Anthony Ghaffari; Otmar Gratzl 📂 Article 📅 2010 🏛 Springer Vienna 🌐 English ⚖ 786 KB

Somatostatin–dopamine ligands in the tre

Somatostatin–dopamine ligands in the treatment of pituitary adenomas

✍ Alexandru Saveanu; Philippe Jaquet 📂 Article 📅 2008 🏛 Springer 🌐 English ⚖ 160 KB

Radiation Therapy in the Multimodal Trea

Radiation Therapy in the Multimodal Treatment Approach of Pituitary Adenoma

✍ Gerd Becker; Martin Kocher; Rolf-Dieter Kortmann; Frank Paulsen; Branislav Jerem 📂 Article 📅 2002 🏛 Springer 🌐 German ⚖ 151 KB

High efficacy without visual damage: The

High efficacy without visual damage: The current status of pituitary radiotherapy

✍ Brian J. Goldsmith; Dennis C. Shrieve; Jay S. Loeffler 📂 Article 📅 1995 🏛 Elsevier Science 🌐 English ⚖ 333 KB

Prognostic factors and results of radiot

Prognostic factors and results of radiotherapy alone in the management of pituitary adenomas

✍ Perry W. Grigsby; Steven Stokes; James E. Marks; Joseph R. Simpson 📂 Article 📅 1988 🏛 Elsevier Science 🌐 English ⚖ 849 KB

Radiotherapy of nonfunctional adenomas o

Radiotherapy of nonfunctional adenomas of the pituitary gland. Results with long-term follow-up

✍ John C. Flickinger; Paul B. Nelson; Augusto Julio Martinez; Melvin Deutsch; Floy 📂 Article 📅 1989 🏛 John Wiley and Sons 🌐 English ⚖ 450 KB 👁 2 views

A total of 112 patients with the diagnosis of nonfunctional pituitary adenoma received radiation therapy at the University of Pittsburgh between 1964 and 1987. Postoperative radiation therapy was administered in 87 patients. Actuarial progression-free survival (tumor control) at 5, 10, 15, and 20 ye